# STEP 1 Drug Database - Pedagogical Mind Map Structure

## ğŸ¯ **LEARNING PHILOSOPHY**
**Order = Understanding**. Each section builds logically from basic mechanisms to complex applications, following how concepts should be learned rather than alphabetical organization.

---

## ğŸ§¬ **AUTONOMIC NERVOUS SYSTEM** *(Foundation - Learn First)*
> **Why First**: Underlies cardiovascular, respiratory, and GI pharmacology

### **A. Cholinergic System**
```
Parasympathomimetics (Cholinomimetics)
â”œâ”€â”€ Direct Agonists â†’ Bethanechol, Pilocarpine
â””â”€â”€ Indirect Agonists (AChE Inhibitors) â†’ Neostigmine, Physostigmine, Pyridostigmine

Parasympatholytics (Antimuscarinics)  
â”œâ”€â”€ Muscarinic Antagonists â†’ Atropine, Scopolamine, Ipratropium, Oxybutynin
â””â”€â”€ Nicotinic Antagonists â†’ Mecamylamine, Succinylcholine, Rocuronium
```

### **B. Adrenergic System**
```
Sympathomimetics
â”œâ”€â”€ Direct Agonists
â”‚   â”œâ”€â”€ Mixed Î±/Î² â†’ Epinephrine  
â”‚   â”œâ”€â”€ Î±1/Î²1 â†’ Norepinephrine
â”‚   â”œâ”€â”€ Î±1 â†’ Phenylephrine
â”‚   â”œâ”€â”€ Î²1/Î²2 â†’ Isoproterenol  
â”‚   â”œâ”€â”€ Î²1 â†’ Dobutamine
â”‚   â””â”€â”€ Î²2 â†’ Albuterol, Salmeterol
â”œâ”€â”€ Indirect Agonists â†’ Amphetamine, Tyramine
â””â”€â”€ Mixed â†’ Ephedrine

Sympatholytics
â”œâ”€â”€ Î±-Blockers â†’ Prazosin, Doxazosin, Phentolamine
â”œâ”€â”€ Î²-Blockers â†’ (see cardiovascular section)
â””â”€â”€ Central Î±2-Agonists â†’ Clonidine, Methyldopa
```

---

## ğŸ«€ **CARDIOVASCULAR SYSTEM** *(Build on Autonomic Foundation)*

### **A. RAAS System** *(The Central Cascade)*
```
The Pathway: Renin â†’ Angiotensin I â†’ ACE â†’ Angiotensin II â†’ Effects

1. ACE Inhibitors (-prils) [Block Conversion]
   â”œâ”€â”€ Captopril â†’ First, contains sulfhydryl group
   â”œâ”€â”€ Enalapril â†’ Prodrug, proven mortality benefit  
   â”œâ”€â”€ Lisinopril â†’ No prodrug, long-acting
   â””â”€â”€ Ramipril â†’ Stroke prevention

2. ARBs (-sartans) [Block AT1 Receptor]
   â”œâ”€â”€ Losartan â†’ First ARB
   â”œâ”€â”€ Valsartan â†’ Heart failure proven
   â”œâ”€â”€ Irbesartan â†’ Renal protection
   â””â”€â”€ Olmesartan â†’ GI side effects

3. Direct Renin Inhibitors â†’ Aliskiren
```

### **B. Adrenergic System** *(Links to Autonomic)*
```
Î²-Blockers [Vaughan-Williams Class II]
â”œâ”€â”€ Non-selective â†’ Propranolol (crosses BBB, anxiety/tremor)
â”œâ”€â”€ Î²1-Selective â†’ Metoprolol, Atenolol, Bisoprolol  
â””â”€â”€ Mixed Î±/Î² â†’ Carvedilol (heart failure proven)

Î±-Blockers [From Sympatholytics]
â””â”€â”€ See autonomic section (Prazosin, Doxazosin)
```

### **C. Calcium System**
```
Calcium Channel Blockers [Vaughan-Williams Class IV]
â”œâ”€â”€ Dihydropyridines (Vascular) [-dipines]
â”‚   â”œâ”€â”€ Nifedipine â†’ Short-acting, can cause hypotension
â”‚   â””â”€â”€ Amlodipine â†’ Long-acting, preferred
â””â”€â”€ Non-Dihydropyridines (Cardiac)
    â”œâ”€â”€ Verapamil â†’ Most cardiac effects, constipation
    â””â”€â”€ Diltiazem â†’ Intermediate selectivity
```

### **D. Diuretics** *(By Nephron Site)*
```
Loop Diuretics [Thick Ascending Limb]
â””â”€â”€ Furosemide â†’ Most potent, ototoxicity

Thiazide Diuretics [Distal Tubule]  
â””â”€â”€ Hydrochlorothiazide â†’ First-line HTN, metabolic effects

K+-Sparing [Collecting Duct]
â”œâ”€â”€ Aldosterone Antagonist â†’ Spironolactone (gynecomastia)
â””â”€â”€ ENaC Blockers â†’ Amiloride, Triamterene
```

### **E. Antiarrhythmics** *(Vaughan-Williams Classification)*
```
Class I: Na+ Channel Blockers
â”œâ”€â”€ Ia â†’ Quinidine (blocks Na+ and K+, â†‘QT)
â”œâ”€â”€ Ib â†’ Lidocaine (shortens AP, damaged tissue)  
â””â”€â”€ Ic â†’ Flecainide (slows conduction, avoid in CAD)

Class II: Î²-Blockers â†’ See adrenergic section

Class III: K+ Channel Blockers  
â””â”€â”€ Amiodarone (pulmonary/thyroid toxicity)

Class IV: Ca2+ Channel Blockers â†’ See calcium system

Miscellaneous
â””â”€â”€ Digoxin (Na+/K+-ATPase, narrow therapeutic index)
```

### **F. Lipid Management**
```
Statins (-statins) [HMG-CoA Reductase Inhibitors]
â”œâ”€â”€ Atorvastatin â†’ Most common
â”œâ”€â”€ Simvastatin â†’ More interactions
â”œâ”€â”€ Rosuvastatin â†’ Most potent
â””â”€â”€ Pravastatin â†’ Hydrophilic, pregnancy-safe
```

### **G. Anticoagulation/Antiplatelet**
```
Anticoagulants
â”œâ”€â”€ Warfarin â†’ Vitamin K antagonist, narrow window
â””â”€â”€ Heparin â†’ Antithrombin III, monitor aPTT

Antiplatelets  
â”œâ”€â”€ Aspirin â†’ Irreversible COX inhibition
â””â”€â”€ Clopidogrel â†’ P2Y12 inhibitor, prodrug
```

### **H. Vasodilators**
```
Nitrates [Venodilation, Preload â†“]
â”œâ”€â”€ Nitroglycerin â†’ Acute, sublingual
â””â”€â”€ Isosorbide mononitrate â†’ Chronic, asymmetric dosing

Direct Vasodilators
â””â”€â”€ Hydralazine â†’ Arterial, lupus-like syndrome
```

---

## ğŸŒ¬ï¸ **RESPIRATORY SYSTEM** *(Uses Autonomic + Some Unique)*

### **A. Bronchodilators** *(From Autonomic System)*
```
Sympathomimetics [Î²2-Agonists]
â”œâ”€â”€ Short-Acting (SABA) â†’ Albuterol (rescue)
â””â”€â”€ Long-Acting (LABA) â†’ Salmeterol (maintenance, + ICS)

Parasympatholytics [Muscarinic Antagonists]  
â”œâ”€â”€ Short-Acting (SAMA) â†’ Ipratropium (COPD first-line)
â””â”€â”€ Long-Acting (LAMA) â†’ Tiotropium (once daily)
```

### **B. Anti-Inflammatory**
```
Corticosteroids
â”œâ”€â”€ Inhaled (ICS) â†’ Beclomethasone (rinse mouth)
â””â”€â”€ Systemic â†’ Prednisone (multiple effects)

Leukotriene Modifiers
â””â”€â”€ Montelukast (oral, psychiatric effects)

Methylxanthines  
â””â”€â”€ Theophylline (narrow therapeutic index)
```

---

## ğŸ§  **NERVOUS SYSTEM** *(Neurotransmitter-Based)*

### **A. GABA System** *(Inhibitory)*
```
GABA Enhancers
â”œâ”€â”€ Benzodiazepines â†’ Lorazepam, Diazepam (anxiolytic, anticonvulsant)
â”œâ”€â”€ Barbiturates â†’ (older, more dangerous)
â””â”€â”€ Z-drugs â†’ Zolpidem (sleep-selective)

GABA in Epilepsy â†’ Valproic acid (broad spectrum)
```

### **B. Glutamate System** *(Excitatory)*
```
Glutamate Antagonists
â”œâ”€â”€ NMDA Antagonists â†’ Ketamine (anesthetic)
â””â”€â”€ AMPA Antagonists â†’ (seizure research)
```

### **C. Sodium Channel System** *(Neuronal Excitability)*
```
Na+ Channel Blockers
â”œâ”€â”€ Antiepileptics â†’ Phenytoin, Carbamazepine, Lamotrigine
â””â”€â”€ Local Anesthetics â†’ Lidocaine (also Class Ib antiarrhythmic)
```

### **D. Dopamine System**
```
Parkinson's Disease [Dopamine â†‘]
â”œâ”€â”€ Dopamine Precursor â†’ Levodopa/Carbidopa
â”œâ”€â”€ Dopamine Agonists â†’ Pramipexole, Ropinirole
â””â”€â”€ MAO-B Inhibitors â†’ Selegiline

Psychosis [Dopamine â†“]  
â”œâ”€â”€ Typical Antipsychotics â†’ Haloperidol (high EPS)
â””â”€â”€ Atypical Antipsychotics â†’ Risperidone (lower EPS)
```

### **E. Serotonin System**
```
Depression [Serotonin â†‘]
â”œâ”€â”€ SSRIs â†’ Fluoxetine, Sertraline, Paroxetine, Citalopram
â”œâ”€â”€ SNRIs â†’ Venlafaxine, Duloxetine  
â”œâ”€â”€ Atypical â†’ Bupropion (DA/NE, no sexual effects)
â””â”€â”€ TCAs â†’ Amitriptyline (anticholinergic)

Migraine â†’ Sumatriptan (5-HT1B/1D agonist)
Nausea â†’ Ondansetron (5-HT3 antagonist)
```

### **F. Mood Stabilizers**
```
Bipolar Disorder
â”œâ”€â”€ Lithium â†’ Narrow therapeutic index, renal/thyroid
â”œâ”€â”€ Valproic acid â†’ Also antiepileptic
â””â”€â”€ Lamotrigine â†’ Also antiepileptic, rash risk
```

---

## ğŸ¦  **ANTIMICROBIALS** *(Target-Based)*

### **A. Cell Wall Synthesis Inhibitors**
```
Î²-Lactams [PBP Binding]
â”œâ”€â”€ Penicillins
â”‚   â”œâ”€â”€ Natural â†’ Penicillin G (narrow spectrum)
â”‚   â””â”€â”€ Aminopenicillins â†’ Amoxicillin (broader)
â”œâ”€â”€ Cephalosporins [Generation = Spectrum]
â”‚   â”œâ”€â”€ 1st Gen â†’ Cephalexin (gram +)
â”‚   â”œâ”€â”€ 2nd Gen â†’ Cefuroxime  
â”‚   â”œâ”€â”€ 3rd Gen â†’ Ceftriaxone (CNS penetration)
â”‚   â””â”€â”€ 4th Gen â†’ Cefepime (Pseudomonas)
â””â”€â”€ Glycopeptides â†’ Vancomycin (MRSA, red man syndrome)
```

### **B. Protein Synthesis Inhibitors**
```
30S Ribosome
â”œâ”€â”€ Aminoglycosides â†’ Gentamicin (nephro/ototoxic)
â””â”€â”€ Tetracyclines â†’ Doxycycline (photosensitivity)

50S Ribosome  
â”œâ”€â”€ Macrolides â†’ Azithromycin (QT prolongation)
â””â”€â”€ Lincosamides â†’ Clindamycin (C. diff risk)
```

### **C. DNA/RNA Synthesis Inhibitors**
```
DNA Gyrase â†’ Fluoroquinolones (generations 2â†’4)
â”œâ”€â”€ 2nd Gen â†’ Ciprofloxacin (broad spectrum)
â”œâ”€â”€ 3rd Gen â†’ Levofloxacin (respiratory)
â””â”€â”€ 4th Gen â†’ Moxifloxacin (anaerobes)

DNA Damage â†’ Metronidazole (anaerobes, avoid alcohol)
```

### **D. Folate Synthesis Inhibitors**
```
Sequential Blockade
â””â”€â”€ TMP-SMX (synergistic, PCP prophylaxis)
```

### **E. Antifungals**
```
Ergosterol Synthesis â†’ Fluconazole (azole, many interactions)
Membrane Disruption â†’ Amphotericin B (nephrotoxic, gold standard)
```

### **F. Antivirals**
```
DNA Polymerase â†’ Acyclovir (HSV/VZV, requires viral TK)
```

---

## ğŸ½ï¸ **GASTROINTESTINAL SYSTEM**

### **A. Acid Suppression** *(Stepwise Intensity)*
```
Proton Pump Inhibitors â†’ Omeprazole (irreversible, most potent)
H2 Receptor Antagonists â†’ Ranitidine (less potent than PPIs)
Antacids â†’ (immediate, short-acting)
```

### **B. Motility** *(From Autonomic)*
```
Prokinetic â†’ Uses cholinergic system
Antidiarrheal â†’ Loperamide (peripheral opioid agonist)
```

### **C. Nausea/Vomiting** *(Neurotransmitter-Based)*
```
5-HT3 Antagonists â†’ Ondansetron (chemo-induced)
D2 Antagonists â†’ Metoclopramide (prokinetic + antiemetic)
```

---

## ğŸ©¸ **ENDOCRINE SYSTEM**

### **A. Diabetes** *(Glucose Homeostasis)*
```
Insulin â†’ Multiple formulations (rapid â†’ long-acting)

Non-Insulin Antidiabetics
â”œâ”€â”€ Metformin â†’ Decreases hepatic glucose production
â”œâ”€â”€ Sulfonylureas â†’ Glipizide, Glyburide (hypoglycemia risk)  
â”œâ”€â”€ TZDs â†’ Pioglitazone (insulin sensitizer, heart failure risk)
â”œâ”€â”€ DPP-4 Inhibitors â†’ Sitagliptin (weight neutral)
â””â”€â”€ GLP-1 Agonists â†’ Exenatide (weight loss, pancreatitis)
```

### **B. Thyroid**
```
Hypothyroidism â†’ Levothyroxine (T4 replacement)
Hyperthyroidism â†’ Methimazole (thyroid peroxidase inhibition)
```

### **C. Corticosteroids** *(Crosses Multiple Systems)*
```
Systemic â†’ Prednisone (multiple effects, taper slowly)
Inhaled â†’ Beclomethasone (respiratory)
```

---

## ğŸ’Š **ANALGESICS/ANTI-INFLAMMATORY**

### **A. NSAIDs** *(COX Selectivity)*
```
Non-Selective â†’ Aspirin (irreversible), Ibuprofen (reversible)
COX-2 Selective â†’ Celecoxib (lower GI risk, higher CV risk)
```

### **B. Gout**
```
Acute â†’ Colchicine (microtubule inhibitor)
Chronic â†’ Allopurinol (xanthine oxidase inhibitor)
```

---

## ğŸ§¬ **ONCOLOGY/IMMUNOLOGY**

### **A. Antimetabolites**
```
Folate Antagonist â†’ Methotrexate (+ folic acid supplementation)
```

### **B. Alkylating Agents**  
```
Cyclophosphamide â†’ Hemorrhagic cystitis (give mesna)
```

---

## ğŸ¯ **LEARNING PATHWAYS & CROSS-REFERENCES**

### **Major Cross-System Connections:**
1. **Autonomic â†’ Cardiovascular** (Î²-blockers, Î±-blockers)
2. **Autonomic â†’ Respiratory** (Î²2-agonists, muscarinic antagonists)  
3. **Sodium Channels** â†’ Cardiac (antiarrhythmics) + Neuro (antiepileptics) + Local anesthetics
4. **Corticosteroids** â†’ Endocrine + Respiratory + Inflammatory
5. **Serotonin** â†’ Depression + Migraine + Nausea
6. **Cholinesterase Inhibitors** â†’ Autonomic + Alzheimer's + Myasthenia Gravis

---

This structure transforms your database from a **reference tool** into a **learning progression** that builds understanding systematically!